Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KVA12123 |
Synonyms | |
Therapy Description |
KVA12123 is a monoclonal antibody that targets the negative checkpoint regulator VSIR (VISTA; PD1H) (Cancer Res (2023) 83 (7_Supplement): 972). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KVA12123 | KVA-12123|KVA 12123 | VSIR Antibody 6 | KVA12123 is a monoclonal antibody that targets the negative checkpoint regulator VSIR (VISTA; PD1H) (Cancer Res (2023) 83 (7_Supplement): 972). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05708950 | Phase Ib/II | KVA12123 + Pembrolizumab KVA12123 | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | Recruiting | USA | 0 |